Talphera IncNASDAQ:TLPH
- LAST PRICE0.9007
- TODAY'S CHANGE (%)-0.0393 (-4.1801%)
- Bid / Lots0.8702/ 1
- Ask / Lots0.9200/ 14
- Open / Previous Close0.9000 / 0.9400
- Day Range
- 52 Week Range
- Volume6,851
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLPH |
|---|---|---|
| 09:32 ET | 224 | 0.9 |
| 09:41 ET | 395 | 0.8796 |
| 09:48 ET | 100 | 0.9033 |
| 10:14 ET | 100 | 0.9 |
| 10:17 ET | 166 | 0.8826 |
| 10:21 ET | 100 | 0.9 |
| 10:26 ET | 223 | 0.8826 |
| 10:30 ET | 100 | 0.9 |
| 11:00 ET | 100 | 0.89248 |
| 11:22 ET | 300 | 0.900201 |
| 11:29 ET | 297 | 0.92 |
| 11:31 ET | 200 | 0.92 |
| 12:14 ET | 100 | 0.94 |
| 12:30 ET | 500 | 0.92 |
| 12:34 ET | 200 | 0.9201 |
| 12:43 ET | 100 | 0.93 |
| 12:56 ET | 200 | 0.93 |
| 02:26 ET | 100 | 0.925 |
| 02:27 ET | 500 | 0.929608 |
| 02:29 ET | 132 | 0.9201 |
| 02:36 ET | 100 | 0.92495 |
| 03:00 ET | 106 | 0.92 |
| 03:05 ET | 100 | 0.92 |
| 03:32 ET | 136 | 0.9 |
| 03:41 ET | 700 | 0.92 |
| 03:56 ET | 513 | 0.900707 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Talphera Inc | 16.0M | -1.0x | --- |
TherapeuticsMD Inc | 17.4M | -2.9x | --- |
Allied Corp | 19.2M | -1.7x | --- |
SYBLEU Inc | 5.9M | -1.4x | --- |
Sentient Brands Holdings Inc | 3.9M | -4.2x | --- |
Resonate Blends Inc | 3.5M | -0.5x | --- |
Company Information
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Contact Information
- Headquarters
- 1850 Gateway Drive, Suite 175SAN MATEO, CA, United States 94404
- Phone
- 650-216-3500
- Fax
- 650-216-6500
Executives
- Independent Chairman of the Board
- Adrian Adams
- Chief Executive Officer, Director
- Vincent Angotti
- Co-Founder, Chief Medical Officer
- Pamela Palmer
- Chief Financial Officer
- Raffi Asadorian
- Chief Development Officer
- Shakil Aslam
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.0M |
|---|---|
Revenue (TTM) | $651.0K |
Shares Outstanding | 17.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $-0.89 |
Book Value | $0.83 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 24.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,235.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
